|Monday, 29 October 2018, 08:45 HKT/SGT|
|Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients.|
TOKYO, Oct 29, 2018 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD.
A late-breaking oral presentation and a poster included data from patients treated with aducanumab for up to 36 and 48 months. Data from both analyses showed a reduction in amyloid plaque levels in a dose- and time-dependent manner, as measured by positron emission tomography (PET). In addition, analyses of exploratory clinical endpoints, Clinical Dementia Rating Sum of Boxes (CDR-SB) and the Mini-Mental State Examination (MMSE), suggested a continued slowing of clinical decline over 36 months and 48 months. The results in each dosing arm were generally consistent with previously reported analyses of this study, and there were no changes to the risk-benefit profile of aducanumab.
"This Phase 1b study now has four years of aducanumab results, and we are encouraged by these data, which continued to show a reduction in amyloid plaque levels and suggest our investigational therapy may slow clinical progression of the disease," said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen. "The Phase 3 studies are now fully enrolled, and we remain driven by the profound unmet needs of patients, families, caregivers and society."
About the Phase 1b Study
The Phase 1b study is a randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of aducanumab in patients with prodromal AD or mild AD dementia. The primary endpoint for the study was safety. Other endpoints (amyloid reduction, CDR-SB and MMSE) were exploratory.
The study included fixed dosing at 1, 3, 6 and 10 mg/kg as well as an arm with a titration regimen up to 10 mg/kg in a cohort of ApoE epsilon4 carriers only.
In the Phase 1b study, 196 patients received aducanumab or placebo, of which 143 entered the LTE. All patients who continued in the LTE were switched to, or continued on, aducanumab treatment. The LTE cohorts were allocated across six dosing arms including: placebo switchers (n=37), 1 mg/kg switchers to 3 mg/kg (n=19), fixed doses (3 mg/kg [n=26], 6 mg/kg [n=24], 10 mg/kg [n=19]) and titration (n=18). There were discontinuations, as expected in studies of 36 or more months. As a result, there are smaller patient numbers in the LTE over time.
Of the 185 patients dosed with aducanumab in the Phase 1b study, 46 patients experienced amyloid- related imaging abnormalities (ARIA)-E (edema). Eight patients experienced more than one episode of ARIA-E. The majority of ARIA events occurred early in the course of treatment; they were typically mild radiographically, clinically asymptomatic and resolved or stabilized within 4-12 weeks, with most patients continuing treatment. In the Phase 1b study, the most commonly reported adverse events were headache, fall and ARIA. There were no new incident cases of ARIA-E since the last interim analysis.
Amyloid plaque levels in the 10 mg/kg fixed dose at 36 months remained at a level considered below the quantitative cut-point that discriminates between a positive and negative scan.
Clinical effects with titrated aducanumab in the second year of the LTE were generally consistent with findings in the 10 mg/kg fixed-dose cohorts.
Amyloid plaque levels were measured by PET using the standardized uptake value ratio (SUVR), and continued to decline in those who remained on treatment for 36 months.
The exploratory endpoints, CDR-SB and the MMSE, measure cognitive and functional decline associated with AD. The results of these assessments suggest a continued slowing of clinical decline during the third year of treatment with aducanumab in certain groups.
The expected average dose for the titration cohort at 36 months was 8.4 mg/kg. At 36 months, a reduction of amyloid plaque (versus placebo) was observed in all fixed-dose and titration arms in a dose- and time-dependent manner. The changes in amyloid plaque, CDR-SB and MMSE are detailed below.
In patients treated up to 48 months, amyloid plaque continued to decrease in a dose- and time-Amyloid plaque levels in the 10 mg/kg fixed-dose at 48 months remained at a level considered below the quantitative cut-point that discriminates between a positive and negative scan. The changes in amyloid plaque, CDR-SB and MMSE are detailed below.
Phase 3 Studies
In July 2018, enrollment was completed for the Phase 3 aducanumab ENGAGE and EMERGE studies, designed to evaluate the efficacy and safety of aducanumab in slowing cognitive and functional impairment in people with early Alzheimer's disease.
Aducanumab (BIIB037) is an investigational compound being studied for the treatment of early Alzheimer's disease. Biogen licensed aducanumab from Neurimmune under a collaboration and license agreement. Aducanumab is a human monoclonal antibody (mAb) derived from a d-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform called Reverse Translational Medicine (RTM). As of October 2017, Biogen and Eisai Co., Ltd. are collaborating on the development and commercialization of aducanumab globally.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media: Twitter, LinkedIn, Facebook, YouTube.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Biogen Inc. David Caouette
Eisai Co., Ltd.
Public Relations Department
Oct 29, 2018 08:45 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Apr 8, 2019 13:06 HKT/SGT|
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090|
|Apr 8, 2019 10:43 HKT/SGT|
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor|
|Apr 5, 2019 09:45 HKT/SGT|
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug|
|Mar 29, 2019 10:46 HKT/SGT|
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease|
|Mar 22, 2019 10:37 HKT/SGT|
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease|
|Mar 22, 2019 10:23 HKT/SGT|
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases|
|Mar 21, 2019 23:25 HKT/SGT|
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease|
|Mar 12, 2019 07:43 HKT/SGT|
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia|
|Mar 7, 2019 11:30 HKT/SGT|
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan|
|Feb 27, 2019 10:52 HKT/SGT|
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan|
|More news >>|